{"id":64010,"date":"2026-03-12T19:29:03","date_gmt":"2026-03-12T13:59:03","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/"},"modified":"2026-03-12T19:29:03","modified_gmt":"2026-03-12T13:59:03","slug":"stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi","status":"publish","type":"post","link":"https:\/\/new.matribhumisamachar.com\/en\/2026\/03\/12\/stonegate-capital-partners-updates-coverage-on-neonc-technologies-holdings-inc-nthi\/","title":{"rendered":"Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)"},"content":{"rendered":"<p style=\"text-align: justify;\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/288256\/511\" width=\"2\" height=\"2\" \/><\/p>\n<p style=\"text-align: justify;\">Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment including BBB penetration and MGMT-driven resistance. Its platform includes NEO100 and NEO212, discussed in further detail below. Beyond its lead programs, NeOnc&#8217;s platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. Lastly, NTHI recently led a successful PIPE offering, adding a gross $16.0M to the Company&#8217;s balance sheet.<\/p>\n<p style=\"text-align: justify;\">To view the full announcement, including downloadable images, bios, and more, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/EZNAPUj2Rn\">click here<\/a>.<\/p>\n<p style=\"text-align: justify;\"><b>Key Takeaways:<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li>NEO212 (oral chemotherapy): A next-generation version of temozolomide designed to improve blood-brain barrier penetration and overcome MGMT-driven resistance in glioblastoma (GBM), targeting a large population where standard TMZ therapy frequently fails.<\/li>\n<li>NEO212 clinical momentum: Phase 1 dose escalation in recurrent GBM has completed with a Recommended Phase 2 Dose of 610 mg established and early signs of disease control observed, positioning the program to advance into Phase 2 efficacy evaluation.<\/li>\n<li>NEO100 (intranasal therapy): A non-invasive drug delivery approach targeting recurrent GBM, with Phase 2 data showing radiographic responses and improved progression-free survival versus historical salvage benchmarks.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/api.newsfilecorp.com\/redirect\/xExGBcKarb\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/7294\/288256_figure1.png\" alt=\"Cannot view this image? Visit: https:\/\/images.newsfilecorp.com\/files\/7294\/288256_figure1.png\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><i>Click image above to view full announcement.<\/i><\/p>\n<hr \/>\n<p style=\"text-align: justify;\"><strong>About Stonegate<br \/>\n<\/strong>Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.<\/p>\n<div style=\"text-align: justify;\">\n<p><b>Contacts:<\/b><\/p>\n<p>Stonegate Capital Partners<br \/>\n(214) 987-4121<br \/>\n<a href=\"mailto:info@stonegateinc.com\">info@stonegateinc.com<\/a><\/p>\n<p>Source: <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/7noYzuMeWv\">Stonegate, Inc.<\/a><\/p>\n<\/div>\n<p style=\"text-align: justify;\">To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/eje3xuMzBO\">https:\/\/www.newsfilecorp.com\/release\/288256<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dallas, Texas&#8211;(Newsfile Corp. &#8211; March 12, 2026) &#8211; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company&#8217;s lead program, NEO212, [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":106422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[54732],"tags":[],"class_list":["post-64010","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases"],"_links":{"self":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/64010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=64010"}],"version-history":[{"count":0,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/64010\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media\/106422"}],"wp:attachment":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=64010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=64010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=64010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}